Evista

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. .
[PubChem].

Medicinal name:
  • Raloxifene Hydrochloride 60 MG Oral Tablet [Evista]

Evista - Pharmacology:

Evista binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Evista produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women. Evista also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen.

Evista mini report

Evista NDA
NDA - A product marketed under an approved New Drug Application
Evista HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Evista global name
Raloxifene hydrochloride
Start - Stop data
START DATA:
1998-Jan-06
Start - Stop data
STOP DATA
not occurred

Evista for patients

For safe and effective use of EVISTA, the physician should inform patients about the following:

Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.

Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.

Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.

Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.

Evista Interactions

Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.

Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. However, 10% decreases in prothrombin time have been observed in single-dose studies. If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.

Other Highly Protein-Bound Drugs: Evista is more than 95% bound to plasma proteins. In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.

See also CLINICAL PHARMACOLOGY, Drug-Drug Interactions

Evista Contraindications

EVISTA is contraindicated in women who are or may become pregnant. EVISTA may cause fetal harm when administered to a pregnant woman. In rabbit studies, abortion and a low rate of fetal heart anomalies (ventricular septal defects) occurred in rabbits at doses ³ 0.1 mg/kg (³ 0.04 times the human dose based on surface area, mg/m2), and hydrocephaly was observed in fetuses at doses ³10 mg/kg (³ 4 times the human dose based on surface area, mg/m2). In rat studies, retardation of fetal development and developmental abnormalities (wavy ribs, kidney cavitation) occurred at doses ³ 1mg/kg (³0.2 times the human dose based on surface area, mg/m2). Treatment of rats at doses of 0.1 to 10 mg/kg (0.02 to 1.6 times the human dose based on surface area, mg/m2) during gestation and lactation produced effects that included delayed and disrupted parturition; decreased neonatal survival and altered physical development; sex-and age-specific reductions in growth and changes in pituitary hormone content; and decreased lymphoid compartment size in offspring. At 10 mg/kg, raloxifene disrupted parturition which resulted in maternal and progeny death and morbidity. Effects in adult offspring (4 months of age) included uterine hypoplasia and reduced fertility; however, no ovarian or vaginal pathology was observed. The patient should be apprised of the potential hazard to the fetus if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug.

EVISTA is contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.

EVISTA is contraindicated in women known to be hypersensitive to raloxifene or other constituents of the tablets.

Manufacturers name:

  • PD-Rx Pharmaceuticals, Inc
  • Eli Lilly and Company
  • Physicians Total Care, Inc
  • Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC

Generic name, Overdose, Half Life Evista, Food Interactions, Chemical, etc..

Evista see also FDA report Saw Palmetto

Brand Names containing Raloxifene
Women's Health